Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: Vebreltinib; Drug: PLB1004 Sponsors: Avistone Biotechnology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials